NEW YORK (GenomeWeb) – BioMark Diagnostics today announced it is partnering with The Metabolomics Innovation Centre on cancer research.
The deal augments BioMark's efforts to discover, validate, and translate metabolomics-based diagnostic tests for early cancer detection, the Vancouver, British Columbia-based firm said, adding it "complements" its planned research into lung, prostate, breast, and colon cancer.
In collaboration with TMIC, BioMark plans to develop novel point-of-care diagnostic tests.
BioMark develops non-invasive technologies to detect cancers, monitor patients, and assess disease treatments. TMIC is a Genome Canada-funded Science & Technology Innovation Centre for metabolomics research, technology development, and services. Its technologies are based on mass spectrometry, NMR, gas chromatography, and novel bioinformatics tools.